Manica Balasegaram and Laura J. V. Piddock
ACS Infectious Diseases
DOI: 10.1021/acsinfecdis.0c00101
Abstract
The Global Antibiotic Research and Development Partnership (GARDP) brings together public and private partners to accelerate the development and global availability of new antibiotics to treat the most challenging drug-resistant bacterial infections. Established in 2016, GARDP’s recently launched strategy sets out its ambitious aim to deliver five new treatments by 2025, focusing on sexually transmitted infections, sepsis in newborns, and infections in hospitalized adults and children.
Click here to read the article